Jin Meilan, Dewa Yasuaki, Kawai Masaomi, Nishimura Jihei, Saegusa Yukie, Kemmochi Sayaka, Harada Tomoaki, Shibutani Makoto, Mitsumori Kunitoshi
Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo 183-8509, Japan.
Toxicology. 2009 Oct 1;264(1-2):16-25. doi: 10.1016/j.tox.2009.07.006. Epub 2009 Jul 28.
To investigate possible potential inducing preneoplastic lesions in liver and in vivo genotoxic potential of diheptyl phthalate (DHP), male F344 rats were subjected to repeated oral administration of DHP at 0, 2.5 or 5 g/kg/day for 28 days. In addition, F344 rats were subjected to once or 14 repeated oral administrations of 5 g/kg/day of DHP, and their livers were subjected to analysis in an alkaline single-cell gel electrophoresis (comet) assay. Furthermore, based on the results of these studies, partial hepatectomized male F344 rats given once, three times, and 14 repeated oral administration of 0, 2.5 or 5 g/kg body weight of DHP were examined by an in vivo liver initiation assay. In a 28-day repeated dose toxicity study, the number and area of glutathione-S-transferase placental form (GST-P) positive foci, a marker of hepatocellular preneoplastic lesions in rats, were significantly increased in DHP-treated groups compared with controls. At 24h after the 14 repeated administrations of DHP, DNA migration, a marker of DNA damage in the comet assay, was significantly induced in DHP-treated rat livers, whereas single treatment did not show such an alteration. In an in vivo liver initiation assay, a significant increase in the number and area of GST-P positive foci was observed in DHP-treated groups subjected to 14 repeated oral administrations of DHP as compared with the control group. These results indicate that DHP may induce altered hepatocellular foci in liver of rats which suggests that DHP is a genotoxic carcinogen in the liver of rats.
为了研究邻苯二甲酸二庚酯(DHP)在肝脏中诱导癌前病变的潜在可能性及其体内遗传毒性潜力,将雄性F344大鼠每天以0、2.5或5 g/kg的剂量重复口服DHP,持续28天。此外,对F344大鼠进行一次或14次5 g/kg/天的DHP重复口服给药,并对其肝脏进行碱性单细胞凝胶电泳(彗星)分析。此外,根据这些研究结果,对部分肝切除的雄性F344大鼠分别进行一次、三次和14次0、2.5或5 g/kg体重的DHP重复口服给药,并通过体内肝脏启动试验进行检测。在一项为期28天的重复剂量毒性研究中,与对照组相比,DHP处理组中大鼠肝细胞癌前病变标志物谷胱甘肽-S-转移酶胎盘型(GST-P)阳性灶的数量和面积显著增加。在DHP重复给药14次后的24小时,彗星试验中DNA损伤的标志物DNA迁移在DHP处理的大鼠肝脏中显著诱导,而单次给药未显示出这种改变。在体内肝脏启动试验中,与对照组相比,接受14次DHP重复口服给药的DHP处理组中GST-P阳性灶的数量和面积显著增加。这些结果表明,DHP可能诱导大鼠肝脏中肝细胞灶的改变,这表明DHP是大鼠肝脏中的一种遗传毒性致癌物。